“To amend the Public Health Service Act to expand research and education with respect to endometrial cancer, and for other purposes.”
No CRS summary available for this bill.
This section states congressional findings on endometrial cancer, including that it is the most common form of uterine cancer and the fourth most common cancer diagnosed in women; primarily affects postmenopausal women ages 55-64 and women with polycystic ovary syndrome or uterine leiomyoma; has increasing incidence rates in the United States (2.5% annual percent change), particularly aggressive subtypes among African-American and Asian women; and that African-American women have higher mortality rates than non-Hispanic White women despite lower incidence rates, with disparities potentially linked to delays in care, late-stage diagnosis, treatment initiation, and socioeconomic factors.
This section establishes a new endometrial cancer program at the National Institutes of Health (NIH) requiring the NIH Director to (1) expand, intensify, and coordinate research on endometrial cancer; (2) communicate diagnosis disparities between African-American women and non-Hispanic White women, along with new research findings, to medical professionals and researchers including via the endometrial cancer public education program; and (3) ensure proportional representation of African-American women in relevant NIH clinical trials based on incidence rates. The NIH Director must coordinate these activities with the directors of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Minority Health and Health Disparities, and Office of Research on Women's Health. For this purpose, $1 million is authorized for each of FY2026 through 2028. This section also establishes an endometrial cancer public education program at the Centers for Disease Control and Prevention (CDC) requiring the CDC Director, in consultation with the Health Resources and Services Administration Administrator, to develop and disseminate public materials on endometrial cancer incidence, risk factors (including elevated risks for ethnic minority women), and treatments—including materials targeted to African-American women—with transmission authorized to nonprofits, higher education institutions, government agencies, and media. Such sums as necessary are authorized for each of FY2026 through 2028.